Alcon vs Genmab

Alcon (ALC), health care, and Genmab (GMAB), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Alcon is worth $35.6B on the stock market and Genmab $32B: Alcon is valued at 11% more. Alcon trades at 54.1 times earnings and Genmab at 44.4; operating margins in their latest fiscal years were 13.1% and 28.6%. Over the past year Alcon's share price has moved -2.82% and Genmab's +70.1%.

Key facts

Alcon market value
$35.6B
Genmab market value
$32B
Alcon P/E
54.1
Genmab P/E
44.4
Alcon revenue
$10.4BFY to 2025-12-31
Genmab revenue
$3.7BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Alcon vs Genmab: every measure side by side
Measure Alcon Genmab
SectorHealth CareHealth Care
Country Switzerland Denmark
Fiscal year ends2025-12-312025-12-31
Size
Market cap$35.6Bhigher$32Blower
Revenue$10.4Bhigher$3.7Blower
Earnings$980Mhigher$963Mlower
Employees25,942higher3,244lower
Total assets$31.6Bhigher$12.9Blower
Valuation
P/E54.1higher44.4lower
P/S3.4lower8.6higher
P/B——
Dividend yield——
Profitability
Operating margin13.1%lower28.6%higher
Balance sheet
Net assets$22Bhigher$5.8Blower
Total liabilities$9.5Bhigher$7Blower
Total debt$4.7Blower$5.3Bhigher
Cash on hand$1.5Blower$1.7Bhigher
Price change
Today+0.64%lower+0.76%higher
1 year-2.82%lower+70.1%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Genmab only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns ALC · Who owns GMAB

Further comparisons

Learn

Questions and answers

Which is bigger, Alcon or Genmab?

By market value, Alcon is the larger: $35.6B against $32B for Genmab. By revenue in its latest fiscal year, Alcon is the larger: $10.4B against $3.7B for Genmab.

Which has the higher P/E ratio?

Alcon: 54.1, against 44.4 for Genmab. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Genmab: 28.6%, against 13.1% for Alcon. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Genmab: $5.3B, against $4.7B for Alcon. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Alcon and Genmab?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Alcon and 1 holds Genmab.

Cite this page

Funkfolio, “Alcon vs Genmab”, data as of 18 November 2026. https://funkfolio.com/compare/alc-vs-gmab

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.